Tirzepatide

Tirzepatide is a single modified peptide that activates receptors for two meal-related hormones, GIP and glucagon-like peptide-1 (GLP-1). Its trials show substantial average weight reduction and glucose lowering, with further evidence in obstructive sleep apnea, cardiovascular disease and heart failure associated with obesity. The approved products, Mounjaro and Zepbound, share the active molecule but carry different indications. Those distinctions changed during 2026 and are essential to interpreting the current research.

Overview

Molecular profile

Type: Modified peptide based on GIP; 39 amino acids Source
Chemical form: Tirzepatide active peptide in Mounjaro and Zepbound pharmaceutical formulations Source
Molecular formula: C225H348N48O68 (tirzepatide active peptide) Source
Molecular weight: 4813.53 Da (tirzepatide active peptide) Source
Structural modifications: Aib at positions 2 and 13; C-terminal amide; C20 (20-carbon) fatty-diacid attachment through a linker at Lys20 Source
Primary targets: GIP and GLP-1 receptors Source

Forms and derivatives

Mounjaro

The diabetes product's August 2026 label includes glucose control from age ten and major cardiovascular-event risk reduction in high-risk adults with type 2 diabetes.

Zepbound

The product is approved for adult weight management and moderate-to-severe obstructive sleep apnea with obesity. The current label characterizes elimination in overweight/obesity and OSA cohorts.

GIP means glucose-dependent insulinotropic polypeptide. Like GLP-1, it helps the pancreas respond to nutrients. Tirzepatide was developed from a GIP-based peptide sequence that also activates the GLP-1 receptor. Coskun and colleagues (2018) connected receptor experiments, animal studies and an early human trial in the development of LY3298176, the compound later named tirzepatide. Its fatty-acid attachment promotes albumin binding and prolonged exposure.

Mounjaro and Zepbound are pharmaceutical presentations of tirzepatide. A premixed preparation with an added ingredient has an additional formulation question: the established molecule's clinical trials do not characterize the added material or the resulting preparation. FDA's current assessment of unapproved GLP-1 products documents concerns about unapproved tirzepatide products, including quality and medication errors.

Uses and research areas

The August 2026 Mounjaro label covers glucose control in adults and children aged 10 years or older with type 2 diabetes. It now also includes reduction of major cardiovascular events in adults with type 2 diabetes at high risk for those events. The cardiovascular indication was added in August 2026, so older accounts of its approved uses can be incomplete.

The August 2026 Zepbound label covers long-term weight management in adults with obesity, or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. Heart failure with preserved ejection fraction is a further research area supported by SUMMIT; it is not listed as a separate indication in these labels.

Mechanism of action

Tirzepatide brings two receptor signals into one peptide. In pancreatic beta cells, GIP and GLP-1 receptor activation enhance glucose-dependent insulin secretion. Insulin helps tissues take up and store glucose, while changes in glucagon secretion reduce excessive liver glucose output in hyperglycemia. The receptor experiments and clinical proof-of-concept work in Coskun and colleagues (2018) establish activity at both receptors. They do not quantify how much each receptor contributes to every later clinical outcome.

Reduced food intake connects this endocrine activity to weight change. Tirzepatide also slows gastric emptying, with the strongest effect after initial exposure and attenuation during continued treatment. The Mounjaro label, sections 12.1–12.2 describes effects on insulin secretion, insulin sensitivity, glucagon and gastric emptying. In sleep apnea, weight reduction can reduce burdens that favor upper-airway collapse. In heart failure associated with obesity, reduced metabolic and mechanical stress offers a rationale for studying symptoms and clinical events. Those disease-specific outcomes require their own trials because a change in weight alone cannot specify their magnitude.

Pharmacokinetics

The fatty-acid modification and albumin binding prolong circulating exposure. After subcutaneous administration, the concentration rises as the peptide is absorbed and later falls as its backbone and fatty-acid portion are metabolized. The two current manufacturer labels describe elimination in slightly different terms: Mounjaro section 12.3 gives approximately five days, while Zepbound section 12.3 gives five to six days in people with overweight or obesity and in people with obstructive sleep apnea and obesity. The Zepbound range identifies its characterized populations.

Tirzepatide: five-to-six-day elimination context

Population: People with overweight or obesity, including OSA with obesity, characterized by Zepbound; Mounjaro supplies the approximately five-day comparison. Administration: subcutaneous administration; illustration begins in the post-absorption elimination phase. Analyte: circulating tirzepatide parent peptide.

This calculated line illustrates tirzepatide elimination after injections under the skin in people with overweight or obesity, including obesity with sleep apnea. The main curve uses a five-day half-life, meaning that the concentration falls by half every five days. Alternative curves use the five-to-six-day range described in the Zepbound label. This approximate label range is not a confidence interval. The model begins after absorption at an arbitrary 100% concentration and applies C/C0 = 2^(-t/t_half). Five- and six-day half-lives determine the shaded range; the main line uses five days. This model tracks parent peptide with constant elimination and leaves absorption, repeated-treatment accumulation and individual variability unmodeled.

Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: US prescribing information. Revised August 2026; DailyMed updated August 28, 2026; Eli Lilly and Company. MOUNJARO (tirzepatide) injection: US prescribing information. Revised August 2026; DailyMed updated August 27, 2026. ZEPBOUND section 12.3, Elimination: approximately 5–6 days in overweight/obesity and OSA with obesity; MOUNJARO section 12.3: approximately 5 days.

The elimination illustration uses five days for its main line and shows the five-to-six-day label range through alternative modeled curves. It starts at a normalized concentration after absorption. That range describes the label's approximate elimination values; it is not a statistical confidence interval. The falling lines contain no measured absorption peak, repeated-treatment accumulation or prediction of a person's clinical response.

Research findings

Weight reduction and direct comparison

Jastreboff and colleagues' SURMOUNT-1 trial (2022) randomized 2,539 adults with obesity or qualifying overweight without diabetes. At 72 weeks, the three assigned tirzepatide groups had average weight reductions of 15.0%, 19.5% and 20.9%, compared with 3.1% with placebo under the treatment-regimen analysis. Gastrointestinal events were mostly mild or moderate. Adverse events led to discontinuation in 4.3%, 7.1% and 6.2% across the active groups versus 2.6% with placebo. The spread across groups and the discontinuations both help explain the reported treatment effect.

Aronne and colleagues' SURMOUNT-5 trial (2025) supplied a direct comparison with injectable semaglutide in adults with obesity without type 2 diabetes. The trial randomized 751 people; 750 received treatment and entered the efficacy and safety analyses. At 72 weeks, least-squares mean weight changes were −20.2% with tirzepatide and −13.7% with semaglutide. The study was open-label and used protocol-defined tolerated exposures, making it a comparison of those treatment strategies in that population.

Malhotra and colleagues (2024) conducted two 52-week SURMOUNT-OSA trials in 469 adults with obesity and moderate-to-severe obstructive sleep apnea. One population was not receiving positive airway pressure at baseline; the other was receiving it. The apnea–hypopnea index counts breathing interruptions or substantial reductions per hour of sleep. Compared with placebo, tirzepatide reduced this index by an additional 20.0 and 23.8 events per hour in the two populations. The separate cohorts are useful because background treatment affects the clinical setting in which the benefit was measured.

In Packer and colleagues' SUMMIT trial (2025; online 2024), 731 participants had obesity and heart failure with preserved ejection fraction. This form of heart failure can impair filling and cause congestion despite a preserved pumping percentage. Cardiovascular death or worsening heart failure occurred in 9.9% with tirzepatide versus 15.3% with placebo over a median 104 weeks, hazard ratio 0.62. The between-group improvement in a heart-failure health-status score was 6.9 points at 52 weeks. Fewer worsening-heart-failure events drove the composite benefit; the cardiovascular-death component was imprecise.

Nicholls and colleagues' SURPASS-CVOT (2025) compared tirzepatide with dulaglutide, a GLP-1 medicine already shown to reduce cardiovascular events, in 13,299 randomized participants with type 2 diabetes and atherosclerotic cardiovascular disease. After 134 participants were excluded for not meeting inclusion criteria, the primary analysis included 13,165. The investigators counted cardiovascular death, heart attack or stroke as one combined outcome. It occurred in 12.2% with tirzepatide and 13.1% with dulaglutide; the hazard ratio was 0.92 with a 95.3% confidence interval of 0.83–1.01. Tirzepatide met the trial's predefined requirement for not being unacceptably worse than dulaglutide, called noninferiority. Although events were numerically less frequent with tirzepatide, the difference was too uncertain to establish superiority (P=0.09). The current approved cardiovascular use is stated separately in the August 2026 Mounjaro label.

A Novo Nordisk announcement dated February 23, 2026 reported the REDEFINE 4 comparison of CagriSema with tirzepatide in 809 adults over 84 weeks. The primary noninferiority endpoint for CagriSema was not met. Reported treatment-regimen weight losses were 20.2% with CagriSema and 23.6% with tirzepatide; estimates assuming treatment adherence were 23.0% and 25.5%. The announcement provides sponsor topline results. Complete trial tables, the noninferiority margin and detailed safety denominators were not available in the retained report, so it cannot supply the same appraisal as a full trial publication.

Safety and tolerability

Nausea, diarrhea, vomiting, constipation and abdominal discomfort are common. Important risks include severe gastrointestinal symptoms, dehydration-associated kidney injury, gallbladder disease, pancreatitis, serious allergy, and hypoglycemia when combined with insulin or an insulin secretagogue. The Zepbound label includes aspiration risk around anesthesia and an August 2026 retinopathy warning addressing temporary worsening with rapid glucose improvement. The current label does not recommend use in severe gastroparesis.

The boxed warning concerns thyroid C-cell tumors in rats, with uncertain human relevance. Contraindications include personal or family medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN2) and serious hypersensitivity. Tirzepatide's effect on gastric emptying can reduce oral contraceptive effectiveness during treatment initiation or escalation, and pregnancy raises fetal-risk concerns. These issues are described in the Mounjaro prescribing information. Clinical selection and monitoring involve these interacting risks alongside the intended benefit.

What the research means

Tirzepatide's evidence has moved beyond weight and glucose measurements into sleep-disordered breathing and clinical cardiovascular outcomes. The results are most useful when the disease setting stays visible. SURMOUNT-OSA measures breathing during sleep, SUMMIT measures worsening heart failure and symptoms, and SURPASS-CVOT compares cardiovascular events against an established treatment. Their different comparators and endpoints explain why one large weight-loss percentage cannot stand in for the entire evidence base.

The direct semaglutide comparison supports greater average weight reduction under the SURMOUNT-5 protocol. The 2026 CagriSema announcement introduces another comparison with less complete public reporting. As head-to-head studies accumulate, the practical interpretation depends on the formulation, tolerability, persistence and clinical outcome being prioritized. Label indications and research findings remain connected but separate pieces of that assessment.

FAQs

What changed in Mounjaro's approved uses during 2026?

The August 2026 manufacturer label added reduction of major cardiovascular events in adults with type 2 diabetes at high risk for those events. The current label also covers glycemic control in adults and children aged ten years or older. Zepbound retains its separate weight-management and sleep-apnea indications.

Why do the two tirzepatide labels describe half-life differently?

Mounjaro gives approximately five days. Zepbound gives five to six days in patients with overweight or obesity and in patients with sleep apnea and obesity. These are approximate descriptions with population context. The illustration shows the reported range and identifies its main five-day line.

Did tirzepatide prove cardiovascular superiority to dulaglutide?

SURPASS-CVOT compared tirzepatide with dulaglutide in people with type 2 diabetes and atherosclerotic cardiovascular disease. Cardiovascular death, heart attack or stroke occurred in 12.2% with tirzepatide and 13.1% with dulaglutide. Tirzepatide met the trial's predefined requirement for not being unacceptably worse than dulaglutide, called noninferiority. The favorable numerical difference was too uncertain to establish that tirzepatide was better (P=0.09). Mounjaro’s August 2026 indication covers reduction of major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. The trial comparison and the indicated population are described in Nicholls and colleagues (2025) and the Mounjaro prescribing information.

What does the sleep-apnea result measure?

The apnea–hypopnea index counts breathing interruptions or reductions per hour of sleep. SURMOUNT-OSA measured improvement in that index in separate groups with and without background positive-airway-pressure treatment. Its design places the benefit in moderate-to-severe sleep apnea associated with obesity. Malhotra and colleagues (2024) report the trials.

Semaglutide and liraglutide activate the GLP-1 receptor alone. CagriSema combines semaglutide with an amylin analogue, while retatrutide adds glucagon-receptor activity to GIP and GLP-1 activity. These preparations illuminate different strategies for coordinating metabolism and appetite. Their clinical comparisons require actual trials, with the active product and the population clearly named.

References

Eli Lilly and Company. MOUNJARO (tirzepatide) injection: US prescribing information. Revised August 2026; DailyMed updated August 27, 2026.
The August label adds cardiovascular risk reduction in adults with high-risk type 2 diabetes and gives the approximately five-day elimination description.
Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: US prescribing information. Revised August 2026; DailyMed updated August 28, 2026.
The obesity and sleep-apnea label characterizes a five-to-six-day elimination half-life and records the August retinopathy warning revision.
US Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Current FDA safety communication; checked October 13, 2026.
The agency explains concerns about unapproved preparations and identifies semaglutide sodium and acetate as different active ingredients from approved semaglutide.
Coskun T, Sloop KW, Loghin C, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism 18:3–14. DOI: 10.1016/j.molmet.2018.09.009.
Receptor pharmacology and early human proof-of-concept connect tirzepatide's dual activity with its molecular design.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine 387(3):205–216. DOI: 10.1056/NEJMoa2206038.
SURMOUNT-1 quantifies weight reduction across assigned tirzepatide groups and reports treatment discontinuation from adverse events.
Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England journal of medicine 393(1):26–36. DOI: 10.1056/NEJMoa2416394.
SURMOUNT-5 directly compares tirzepatide and semaglutide weight outcomes under the same open-label randomized protocol.
Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. The New England journal of medicine 391(13):1193–1205. DOI: 10.1056/NEJMoa2404881.
Two SURMOUNT-OSA populations distinguish the reduction in breathing events with and without baseline positive-airway-pressure treatment.
Packer M, Zile MR, Kramer CM, et al. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine 392(5):427–437. DOI: 10.1056/NEJMoa2410027.
SUMMIT measures worsening heart failure and health status in obesity-associated preserved-ejection-fraction disease; few deaths limit the mortality comparison.
Nicholls SJ, Pavo I, Bhatt DL, et al. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. The New England journal of medicine 393(24):2409–2420. DOI: 10.1056/NEJMoa2505928.
SURPASS-CVOT compared cardiovascular death, heart attack or stroke with tirzepatide and dulaglutide in people with type 2 diabetes and atherosclerotic cardiovascular disease. Tirzepatide met the predefined noninferiority requirement; its favorable numerical event difference was too uncertain to establish superiority.
Novo Nordisk. Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved. Company announcement, 23 February 2026.
The sponsor reports failure of CagriSema's noninferiority endpoint against tirzepatide, with separate treatment-regimen and adherence-assuming weight estimates.
Malhotra A, Bednarik J, Chakladar S, Dunn JP, Weaver T, Grunstein R, Fietze I, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Bunck MC. Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial. Contemporary Clinical Trials. 2024;141:107516. DOI: 10.1016/j.cct.2024.107516.
Describes the SURMOUNT-OSA rationale, trial design and baseline characteristics; the later outcome paper reports the treatment effects.
Eli Lilly and Company; US Food and Drug Administration. ZEPBOUND (tirzepatide) injection: approved prescribing information. Revised January 2026. NDA 217806 supplement 037; FDA Reference ID 5723959.
The January 2026 label provides earlier product pharmacology and safety context; the current August 2026 label supplies the article’s current regulatory and warning information.

Glossary

GIP: Glucose-dependent insulinotropic polypeptide, a nutrient-related hormone that enhances insulin secretion.
GLP-1: Glucagon-like peptide-1, a gut hormone involved in glucose regulation and appetite.
Albumin: A blood protein that binds tirzepatide and helps prolong its circulating exposure.
Apnea–hypopnea index: The number of breathing interruptions or substantial breathing reductions per hour of sleep.
Positive airway pressure: A treatment that uses pressurized air to help keep the airway open during sleep.
Preserved ejection fraction: A preserved percentage of blood pumped per beat; heart failure can still occur because filling and other functions are impaired.
Noninferiority: A prespecified test of whether a treatment performs within an acceptable margin relative to its comparator.
Modified intention-to-treat population: A defined analysis population that may exclude specified participants after randomization; its criteria and denominators matter.
Aib: Aminoisobutyric acid, the amino-acid building block included at two positions in tirzepatide.